lonafarnib has been researched along with tamoxifen in 3 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 20,630 | 2,227 | 6,256 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Basso, AD; Bishop, WR; Kirschmeier, P; Liu, G; Long, BJ; Mirza, A | 1 |
| Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA | 1 |
3 other study(ies) available for lonafarnib and tamoxifen
| Article | Year |
|---|---|
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine | 2001 |
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Caspases; Cell Line, Tumor; Farnesyltranstransferase; Humans; Monomeric GTP-Binding Proteins; Neoplasms; Neuropeptides; Phosphorylation; Piperidines; Protein Kinases; Protein Prenylation; Pyridines; Ras Homolog Enriched in Brain Protein; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases | 2005 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles | 2007 |